<DOC>
	<DOCNO>NCT00622388</DOCNO>
	<brief_summary>The purpose trial determine effect ofatumumab patient Diffused Large B-Cell Lymphoma ( DLBCL ) ineligible transplant relapse autologous transplant</brief_summary>
	<brief_title>Ofatumumab Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma ( DLBCL ) Ineligible Relapse/Progression After Transplant</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients DLBCL relapse complete remission disease progression partial remission ineligible autologous stem cell transplantation relapse complete remission disease progression partial remission follow autologous stem cell transplantation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>